Jones Healthcare & Technology Innovation Conference: Biotech veteran David Hung on his company Nuvation Bio, which has an FDA decision for its ROS1 scheduled for June

He describes where this fits into the ROS1 space, and the data that has been derived for the filing. Plus, mIDH1, drug-drug-conjugates, and his take on the current environment in biotech.